eISSN: 2720-5371
ISSN: 1230-2813
Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Scientific board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

without publication fees

Open access

without publication fees
Share:
Send email
Share:
abstract:
Review article

The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review

I. Putu Eka Widyadharma
1
,
Clarissa Tertia
2
,
Aurelia Vania
3
,
Pamela Tiffani
1
,
I. Gede Eka Wiratnaya
4

  1. Department of Neurology, Faculty of Medicine, Universitas Udayana, Prof. Dr. IGNG Ngoerah General Hospital, Bali,
  2. Department of Neurology, Eka Hospital, Pekanbaru, Indonesia
  3. Atma Jaya Neuroscience and Cognitive Center, Department of Neurology, School of Medicine and Health Science, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
  4. Department of Orthopedic, Faculty of Medicine, Universitas Udayana Prof. Dr. IGNG Ngoerah General Hospital, Bali, Indonesia
Adv Psychiatry Neurol 2024; 33 (3):
DOI: https://doi.org/10.5114/ppn.2024.144603
Online publish date: 2024/10/31
View full text Get citation
 
PlumX metrics:
Purpose:
Skeletal-related events (SREs) are common complications of bone metastases that include the need for radiation or surgery to bone, pathological and radiological fractures, and hypercalcemia. Available data indicate that significant bone pain is associated with SREs, leading to an increased risk of death, higher medication costs, and reduced quality of life for patients. Bisphosphonate agents and denosumab are therapeutic options for preventing SREs in advanced cancer patients with bone metastases. This study aims to compare the effect of denosumab and zoledronic acid in SREs, with a particular focus on pain-related SREs.

Views:
Three scientific databases – PubMed, the Cochrane Library, and Google Scholar – were selected and searched for articles published in English up to March 2023. Also, a manual search of related articles was conducted. From the systematic search, four randomized clinical trial studies were identified and further assessed using the Cochrane Collaboration Risk of Bias Tool.

Conclusions:
Denosumab was found to have outcomes that are not inferior to Zoledronic acid in delaying the first incidence of SREs, which include pathologic fracture, radiotherapy to bone, surgery to bone, or spinal cord compression. This review concludes that both therapies effectively reduce pain and prevent SREs in cancer patients at risk.

keywords:

cancer pain, denosumab, zoledronic acid, bone neoplasm, skeletal related event
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.